Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care

Summary

The overall objective of this study is to develop and pilot test a novel regimen of psilocybin-assisted psychotherapy for demoralization in patients receiving hospice care.

-The name of the study drug involved in this study is Psilocybin

Conditions

• Hospice
• Psilocybin
• Demoralization
• Terminal Illness
• Cancer-related Problem/Condition
• Psychotherapy
• Terminal Cancer
• Cancer Terminal

Interventions

DRUG

Psilocybin

Oral, single administration, dosage 25 mg orally

BEHAVIORAL

Psychotherapy

The treatment regimen consists of a single administration of psilocybin orally combined with a supportive psychotherapy including 2 preparation sessions and 2 integration sessions

Sponsors & Collaborators

• Oppenheimer Family Psychosocial Oncology and Palliative Care Research Grants

  collaborator UNKNOWN

• Usona Institute

  collaborator OTHER

• Carey and Claudia Turnbull Family Foundation

  collaborator UNKNOWN

• Heffter Research Institute

  collaborator OTHER

• George Sarlo Foundation

  collaborator UNKNOWN

• RiverStyx Foundation

  collaborator OTHER

• Council on Spiritual Practices Fund at the San Francisco Foundation

  collaborator UNKNOWN

• Nikean Foundation

  collaborator UNKNOWN

• Jack Smith

  collaborator UNKNOWN

• Yvan Beaussant, MD, MSci

  lead OTHER

Principal Investigators

• Yvan Beaussant, MD · Dana-Farber Cancer Institute

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

21 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-03-09

Primary Completion

2024-07-27

Completion

2025-12-31

FDA Drug

Yes

Countries

• United States

Study Locations